Analysts Rating Network
( ACHN )
12/23/2014 Leerink Swann Boost Price Target Outperform $12.00 - $25.00 View Tweet This Rating Share This Rating on StockTwits
12/22/2014 Maxim Group Set Price Target Buy $22.00 View Tweet This Rating Share ThisRating on StockTwits
12/22/2014 Deutsche Bank Boost Price Target Buy $17.00 - $25.00 Less
and Jaffray $22.50 fly on the wall
Abbie is 12% cheaper than GILD. Black and white insurance Co going to OK Abbie drug and not GILD, that's what they do they will OK the cheaper drug and NOT Ok the more expensive drug since they are both FDA approved.
because they don't if 8 weeks will be enough to cure Hep C, they have to prescribe the 12 weeks.
Dr's and Patients Have NO say. When Insurance Co says they will only except ABBIE that is what the Dr will prescribe
Micheal Yee : Abbie Will Get Market Share
Both FDA Approved , Insurance Not Going to Pay GILD only ABBIE now.
Investor Business Daily
By BRIAN DEAGON, INVESTOR'S BUSINESS DAILY
Houston-based Bellicum is developing cellular immunotherapy for the treatment of cancer. It's a clinical stage biopharmaceutical company focused on developing cellular immunotherapies for various forms of the disease, including hematological cancer and solid tumors, as well as orphan inherited blood disorders.
Solithromycin going to be a blockbuster. A steal here and investors know it, that's why Cempra was green in a sea of red Friday.